Abstract
Poly(ADP-ribose) polymerase 1 (PARP-1) protects the genome by functioning in the DNA damage surveillance network. In response to stresses that are toxic to the genome, PARP-1 activity increases substantially, an event that appears crucial for maintaining genomic integrity. Massive PARP-1 activation, however, can deplete the cell of NAD+ and ATP, ultimately leading to energy failure and cell death. The discovery that cell death may be suppressed by PARP inhibitors or by deletion of the parp-1 gene has prompted a great deal of interest in the process of poly(ADP-ribosyl)ation. Suppression of PARP-1 is capable of protecting against cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The secondary damage of initially surviving neurons in brain stroke accounts for most of the volume of the infarcted area and the subsequent loss of brain function. Microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may therefore be a promising strategy in protecting neurons from this secondary damage, as well. As PARP-1 is now recognised as playing a role also in the regulation of gene transcription, this further increases the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenges the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. PARP(s) might regulate cell fate as essential modulators of death and survival transcriptional programs with relation to NF-κB and p53, proposing that inhibitors of poly(ADP-ribosyl)ation could therefore prevent the deleterious consequences of neuroinflammation by reducing NF-κB activity.
Keywords: poly(adp-ribose) polymerase, dna repair, neurotoxicity, brain ischemia, neurodegeneration, neuroinflammation, neuroprotection, gene transcription
Current Drug Targets - CNS & Neurological Disorders
Title: Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury
Volume: 2 Issue: 5
Author(s): S. D. Skaper
Affiliation:
Keywords: poly(adp-ribose) polymerase, dna repair, neurotoxicity, brain ischemia, neurodegeneration, neuroinflammation, neuroprotection, gene transcription
Abstract: Poly(ADP-ribose) polymerase 1 (PARP-1) protects the genome by functioning in the DNA damage surveillance network. In response to stresses that are toxic to the genome, PARP-1 activity increases substantially, an event that appears crucial for maintaining genomic integrity. Massive PARP-1 activation, however, can deplete the cell of NAD+ and ATP, ultimately leading to energy failure and cell death. The discovery that cell death may be suppressed by PARP inhibitors or by deletion of the parp-1 gene has prompted a great deal of interest in the process of poly(ADP-ribosyl)ation. Suppression of PARP-1 is capable of protecting against cerebral and cardiac ischemia, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism, traumatic spinal cord injury, and streptozotocin-induced diabetes. The secondary damage of initially surviving neurons in brain stroke accounts for most of the volume of the infarcted area and the subsequent loss of brain function. Microglial migration is strongly controlled in living brain tissue by expression of the integrin CD11a, which is regulated in turn by PARP-1, proposing that PARP-1 downregulation may therefore be a promising strategy in protecting neurons from this secondary damage, as well. As PARP-1 is now recognised as playing a role also in the regulation of gene transcription, this further increases the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenges the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. PARP(s) might regulate cell fate as essential modulators of death and survival transcriptional programs with relation to NF-κB and p53, proposing that inhibitors of poly(ADP-ribosyl)ation could therefore prevent the deleterious consequences of neuroinflammation by reducing NF-κB activity.
Export Options
About this article
Cite this article as:
Skaper D. S., Poly(ADP-Ribosyl)ation Enzyme-1 as a Target for Neuroprotection in Acute Central Nervous System Injury, Current Drug Targets - CNS & Neurological Disorders 2003; 2 (5) . https://dx.doi.org/10.2174/1568007033482733
DOI https://dx.doi.org/10.2174/1568007033482733 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
Therapeutic Potential of Nitrate Esters of Commonly Used Drugs
Current Topics in Medicinal Chemistry Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets TRPM8 Biology and Medicinal Chemistry
Current Topics in Medicinal Chemistry Retraction Notice: Prevention of Emetic Episodes During Cesarean Delivery Performed Under Regional Anesthesia in Parturients
Current Drug Safety Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) Detection of the Artery of Adamkiewicz Before Open Surgery and Endovascular Aortic Repair: A Review
Current Medical Imaging Ligament and Tendon Repair through Regeneration Using Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Progress in Drug Treatment of Cerebral Edema
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: The Administration of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Dentistry (Executive Editor: Saynur Vardar)]
Current Pharmaceutical Design AMPK Function in Aging Process
Current Drug Targets Beta-Adrenoreceptor Modulation of Metabolic, Endocrine and Immunologic Function During Critical Illness
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipidomics as Tools for Finding Biomarkers of Intestinal Pathology: From Irritable Bowel Syndrome to Colorectal Cancer
Current Drug Targets The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science The Role of Signaling Pathway in the Biological Cause of Rheumatoid Arthritis
Current Drug Research Reviews Identifying Endogenous Neural Stem Cells in the Adult Brain In Vitro and In Vivo: Novel Approaches
Current Pharmaceutical Design An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Dental Stem Cell in Tooth Development and Advances of Adult Dental Stem Cell in Regenerative Therapies
Current Stem Cell Research & Therapy Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) A New Aspect of the TrkB Signaling Pathway in Neural Plasticity
Current Neuropharmacology Commentary (Brilliant Blue G: What a Little More Colour Can Be)
CNS & Neurological Disorders - Drug Targets